Clinical Trials · NCT05419856
Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- 4Moving Biotech
- Enrollment
- 34
- Start date
- Aug 2022
- Locations
- 3 sites, Belgium
- Primary endpoint
- Safety and Tolerability of Single IA Administration of 4P-004 at Escalating Doses in Participants With Knee OA.